JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

IQVIA Holdings Inc

Aperta

SettoreSettore sanitario

158.59 0.08

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

153.65

Massimo

159.22

Metriche Chiave

By Trading Economics

Entrata

182M

514M

Vendite

264M

4.4B

P/E

Media del settore

20.898

67.147

Margine di Profitto

11.778

Dipendenti

93,000

EBITDA

1B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+41.24% upside

Dividendi

By Dow Jones

Utili prossimi

5 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-12B

28B

Apertura precedente

158.51

Chiusura precedente

158.59

Notizie sul Sentiment di mercato

By Acuity

50%

50%

201 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

IQVIA Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 23:53 UTC

Utili

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Azioni calde

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Utili

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Utili

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Utili

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Utili

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Utili

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Utili

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Utili

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Utili

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Utili

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Utili

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Utili

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Utili

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Utili

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Utili

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Confronto tra pari

Modifica del prezzo

IQVIA Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

41.24% in crescita

Previsioni per 12 mesi

Media 224.54 USD  41.24%

Alto 255 USD

Basso 185 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per IQVIA Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

14

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

150.68 / 153.45Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

201 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat